Rat Study Shows Chrysotile Asbestos Is Strong Carcinogen

This article originally appeared here.
Share this content:
Rat Study Shows Chrysotile Asbestos Is Strong Carcinogen
Rat Study Shows Chrysotile Asbestos Is Strong Carcinogen

(HealthDay News) – Chrysotile, a commercially used type of asbestos, induces malignant mesothelioma (MM) in the rat peritoneal cavity, with pathogenesis strongly linked to iron overload, according to a study published online August 2 in The Journal of Pathology.

To examine the carcinogenicity of chrysotile, Li Jiang, from the Nagoya University Graduate School of Medicine in Japan, and colleagues injected rats with a suspension of standard asbestos in saline. Some of the asbestos-treated rats were injected with 80mg/kg nitrilotriacetate (NTA) to enhance an iron-catalyzed Fenton reaction. Rat samples were analyzed for histological and immunohistochemical characteristics.

The researchers found that the pathogenesis of chrysotile-induced mesothelial carcinogenesis correlated closely with iron overload. The period required for carcinogenesis was significantly reduced with repeated administration of the iron chelator NTA. Peritoneal organs were found to have massive iron deposition. The most frequent genomic alteration in human MM and in iron-induced rodent carcinogenesis—homozygous deletion of the CDKN2A/2B/ARF tumor suppressor genes—was observed in 92.6% of the cases studied with array-based comparative genomic hybridization. There was high expression of mesoderm specific transcription factors Dlx5 and Hand1 in induced rat MM cells, which demonstrated active iron uptake and utilization.

"In conclusion, chrysotile is a strong carcinogen that acts through the induction of local iron overload in vivo when it [reaches] mesothelial cells," the authors write. "Therefore, more appropriate measures have to be taken to reduce environmental cancer risk in this era of human longevity."

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs